Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 28, 2023Blood AdvancesOpen Access

Cost-effectiveness of second-line lisocabtagene maraleucel in relapsed or refractory diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJee H. ChoeUniversity of Southern CaliforniaTYTianzhou YuBrighton HospitalJAJeremy S. AbramsonUniversity of Southern California

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Choe et al. (2023) studied this question.

synapsesocial.com/papers/6a75c5dbf718b06d6813ca31https://doi.org/10.1182/bloodadvances.2023011793
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cost-utility and cost-benefit analysis of TAVR availability in the US severe symptomatic aortic stenosis patient population2022 · 5 citations
  2. 2Chimeric Antigen Receptor T-Cell Therapies: Barriers and Solutions to Access2022 · 137 citations
  3. 3Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel and Tisagenlecleucel in the Third-Line or Later Treatment Setting for Relapsed or Refractory Large B-cell Lymphoma in the United States2023 · 19 citations